Membership
Tour
Register
Log in
Reverse Transcribing RNA Viruses
Follow
Industry
CPC
C12N2740/00
This industry / category may be too specific. Please go to a parent level for more data
Parent Industries
C
CHEMISTRY METALLURGY
C12
Biochemistry
C12N
MICRO-ORGANISMS OR ENZYMES COMPOSITIONS THEREOF PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS MUTATION OR GENETIC ENGINEERING CULTURE MEDIA
Current Industry
C12N2740/00
Reverse Transcribing RNA Viruses
Sub Industries
C12N2740/00011
Reverse Transcribing RNA Viruses
C12N2740/00021
Viruses as such
C12N2740/00022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/00023
Virus like particles [VLP]
C12N2740/00031
Uses of virus other than therapeutic or vaccine
C12N2740/00032
Use of virus as therapeutic agent, other than vaccine
C12N2740/00033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/00034
Use of virus or viral component as vaccine
C12N2740/00041
Use of virus, viral particle or viral elements as a vector
C12N2740/00042
virus or viral particle as vehicle
C12N2740/00043
viral genome or elements thereof as genetic vector
C12N2740/00044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/00045
Special targeting system for viral vectors
C12N2740/00051
Methods of production or purification of viral material
C12N2740/00052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/00061
Methods of inactivation or attenuation
C12N2740/00062
by genetic engineering
C12N2740/00063
by chemical treatment
C12N2740/00064
by serial passage
C12N2740/00071
Demonstrated in vivo effect
C12N2740/00088
For redistribution
C12N2740/10011
Retroviridae
C12N2740/10021
Viruses as such
C12N2740/10022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/10023
Virus like particles [VLP]
C12N2740/10031
Uses of virus other than therapeutic or vaccine
C12N2740/10032
Use of virus as therapeutic agent, other than vaccine
C12N2740/10033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/10034
Use of virus or viral component as vaccine
C12N2740/10041
Use of virus, viral particle or viral elements as a vector
C12N2740/10042
virus or viral particle as vehicle
C12N2740/10043
viral genome or elements thereof as genetic vector
C12N2740/10044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/10045
Special targeting system for viral vectors
C12N2740/10051
Methods of production or purification of viral material
C12N2740/10052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/10061
Methods of inactivation or attenuation
C12N2740/10062
by genetic engineering
C12N2740/10063
by chemical treatment
C12N2740/10064
by serial passage
C12N2740/10071
Demonstrated in vivo effect
C12N2740/10088
For redistribution
C12N2740/11011
Alpharetrovirus
C12N2740/11021
Viruses as such
C12N2740/11022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/11023
Virus like particles [VLP]
C12N2740/11031
Uses of virus other than therapeutic or vaccine
C12N2740/11032
Use of virus as therapeutic agent, other than vaccine
C12N2740/11033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/11034
Use of virus or viral component as vaccine
C12N2740/11041
Use of virus, viral particle or viral elements as a vector
C12N2740/11042
virus or viral particle as vehicle
C12N2740/11043
viral genome or elements thereof as genetic vector
C12N2740/11044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/11045
Special targeting system for viral vectors
C12N2740/11051
Methods of production or purification of viral material
C12N2740/11052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/11061
Methods of inactivation or attenuation
C12N2740/11062
by genetic engineering
C12N2740/11063
by chemical treatment
C12N2740/11064
by serial passage
C12N2740/11071
Demonstrated in vivo effect
C12N2740/11088
For redistribution
C12N2740/12011
Betaretrovirus
C12N2740/12021
Viruses as such
C12N2740/12022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/12023
Virus like particles [VLP]
C12N2740/12031
Uses of virus other than therapeutic or vaccine
C12N2740/12032
Use of virus as therapeutic agent, other than vaccine
C12N2740/12033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/12034
Use of virus or viral component as vaccine
C12N2740/12041
Use of virus, viral particle or viral elements as a vector
C12N2740/12042
virus or viral particle as vehicle
C12N2740/12043
viral genome or elements thereof as genetic vector
C12N2740/12044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/12045
Special targeting system for viral vectors
C12N2740/12051
Methods of production or purification of viral material
C12N2740/12052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/12061
Methods of inactivation or attenuation
C12N2740/12062
by genetic engineering
C12N2740/12063
by chemical treatment
C12N2740/12064
by serial passage
C12N2740/12071
Demonstrated in vivo effect
C12N2740/12088
For redistribution
C12N2740/13011
Gammaretrovirus
C12N2740/13021
Viruses as such
C12N2740/13022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/13023
Virus like particles [VLP]
C12N2740/13031
Uses of virus other than therapeutic or vaccine
C12N2740/13032
Use of virus as therapeutic agent, other than vaccine
C12N2740/13033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/13034
Use of virus or viral component as vaccine
C12N2740/13041
Use of virus, viral particle or viral elements as a vector
C12N2740/13042
virus or viral particle as vehicle
C12N2740/13043
viral genome or elements thereof as genetic vector
C12N2740/13044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/13045
Special targeting system for viral vectors
C12N2740/13051
Methods of production or purification of viral material
C12N2740/13052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/13061
Methods of inactivation or attenuation
C12N2740/13062
by genetic engineering
C12N2740/13063
by chemical treatment
C12N2740/13064
by serial passage
C12N2740/13071
Demonstrated in vivo effect
C12N2740/13088
For redistribution
C12N2740/14011
Deltaretrovirus
C12N2740/14021
Viruses as such
C12N2740/14022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/14023
Virus like particles [VLP]
C12N2740/14031
Uses of virus other than therapeutic or vaccine
C12N2740/14032
Use of virus as therapeutic agent, other than vaccine
C12N2740/14033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/14034
Use of virus or viral component as vaccine
C12N2740/14041
Use of virus, viral particle or viral elements as a vector
C12N2740/14042
virus or viral particle as vehicle
C12N2740/14043
viral genome or elements thereof as genetic vector
C12N2740/14044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/14045
Special targeting system for viral vectors
C12N2740/14051
Methods of production or purification of viral material
C12N2740/14052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/14061
Methods of inactivation or attenuation
C12N2740/14062
by genetic engineering
C12N2740/14063
by chemical treatment
C12N2740/14064
by serial passage
C12N2740/14071
Demonstrated in vivo effect
C12N2740/14088
For redistribution
C12N2740/15011
Lentivirus, not HIV
C12N2740/15021
Viruses as such
C12N2740/15022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/15023
Virus like particles [VLP]
C12N2740/15031
Uses of virus other than therapeutic or vaccine
C12N2740/15032
Use of virus as therapeutic agent, other than vaccine
C12N2740/15033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/15034
Use of virus or viral component as vaccine
C12N2740/15041
Use of virus, viral particle or viral elements as a vector
C12N2740/15042
virus or viral particle as vehicle
C12N2740/15043
viral genome or elements thereof as genetic vector
C12N2740/15044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/15045
Special targeting system for viral vectors
C12N2740/15051
Methods of production or purification of viral material
C12N2740/15052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/15061
Methods of inactivation or attenuation
C12N2740/15062
by genetic engineering
C12N2740/15063
by chemical treatment
C12N2740/15064
by serial passage
C12N2740/15071
Demonstrated in vivo effect
C12N2740/15088
For redistribution
C12N2740/16011
Human Immunodeficiency Virus, HIV
C12N2740/16021
Viruses as such
C12N2740/16022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16023
Virus like particles [VLP]
C12N2740/16031
Uses of virus other than therapeutic or vaccine
C12N2740/16032
Use of virus as therapeutic agent, other than vaccine
C12N2740/16033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/16034
Use of virus or viral component as vaccine
C12N2740/16041
Use of virus, viral particle or viral elements as a vector
C12N2740/16042
virus or viral particle as vehicle
C12N2740/16043
viral genome or elements thereof as genetic vector
C12N2740/16044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/16045
Special targeting system for viral vectors
C12N2740/16051
Methods of production or purification of viral material
C12N2740/16052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/16061
Methods of inactivation or attenuation
C12N2740/16062
by genetic engineering
C12N2740/16063
by chemical treatment
C12N2740/16064
by serial passage
C12N2740/16071
Demonstrated in vivo effect
C12N2740/16088
For redistribution
C12N2740/16111
concerning HIV env
C12N2740/16122
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16134
Use of virus or viral component as vaccine
C12N2740/16171
Demonstrated in vivo effect
C12N2740/16188
For redistribution
C12N2740/16211
concerning HIV gagpol
C12N2740/16222
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16234
Use of virus or viral component as vaccine
C12N2740/16271
Demonstrated in vivo effect
C12N2740/16288
For redistribution
C12N2740/16311
concerning HIV regulatory proteins
C12N2740/16322
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16334
Use of virus or viral component as vaccine
C12N2740/16371
Demonstrated in vivo effect
C12N2740/16388
For redistribution
C12N2740/17011
Spumavirus
C12N2740/17021
Viruses as such
C12N2740/17022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/17023
Virus like particles [VLP]
C12N2740/17031
Uses of virus other than therapeutic or vaccine
C12N2740/17032
Use of virus as therapeutic agent, other than vaccine
C12N2740/17033
Use of viral protein as therapeutic agent other than vaccine
C12N2740/17034
Use of virus or viral component as vaccine
C12N2740/17041
Use of virus, viral particle or viral elements as a vector
C12N2740/17042
virus or viral particle as vehicle
C12N2740/17043
viral genome or elements thereof as genetic vector
C12N2740/17044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/17045
Special targeting system for viral vectors
C12N2740/17051
Methods of production or purification of viral material
C12N2740/17052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/17061
Methods of inactivation or attenuation
C12N2740/17062
by genetic engineering
C12N2740/17063
by chemical treatment
C12N2740/17064
by serial passage
C12N2740/17071
Demonstrated in vivo effect
C12N2740/17088
For redistribution
Industries
Overview
Organizations
People
Information
Impact
Patents Grants
last 30 patents
Information
Patent Grant
Hippo and dystrophin complex signaling in cardiomyocyte renewal
Patent number
11,981,895
Issue date
May 14, 2024
Baylor College of Medicine and Texas Heart Institute
James F. Martin
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Grant
HIV pre-immunization and immunotherapy
Patent number
11,980,663
Issue date
May 14, 2024
American Gene Technologies International Inc.
Charles David Pauza
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Grant
Modified cell with enhanced migration capability
Patent number
11,981,920
Issue date
May 14, 2024
Innovative Cellular Therapeutics Holdings, Ltd.
Chengfei Pu
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Grant
Viral vectors and use thereof in adoptive cellular therapy
Patent number
11,975,025
Issue date
May 7, 2024
Immatics US, Inc.
Melinda Mata
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Non-integrating viral delivery system and methods related thereto
Patent number
11,976,292
Issue date
May 7, 2024
American Gene Technologies International Inc.
Charles David Pauza
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Optimized lentiviral vector for stem cell gene therapy of hemoglobi...
Patent number
11,976,293
Issue date
May 7, 2024
The Regents of the University of California
Donald B. Kohn
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Strong insulator and uses thereof in gene delivery
Patent number
11,970,707
Issue date
Apr 30, 2024
Children's Hospital Medical Center
Punam Malik
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Genome engineering with Type I CRISPR systems in eukaryotic cells
Patent number
11,970,710
Issue date
Apr 30, 2024
Duke University
Charles A. Gersbach
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Use of TREM-1 inhibitors for treatment, elimination and eradication...
Patent number
11,969,427
Issue date
Apr 30, 2024
Emory University
Raymond F. Schinazi
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Methods and compositions for modulating CAR-T activity
Patent number
11,965,022
Issue date
Apr 23, 2024
Sana Biotechnology, Inc.
Sonja Schrepfer
C07 - ORGANIC CHEMISTRY
Information
Patent Grant
Therapeutic targets for facioscapulohumeral muscular dystrophy
Patent number
11,963,975
Issue date
Apr 23, 2024
University of Massachusetts
Peter L. Jones
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Immune synapse-stabilizing chimeric antigen receptor (CAR) T cell
Patent number
11,965,014
Issue date
Apr 23, 2024
TICAROS CO., LTD.
Kyungho Choi
C07 - ORGANIC CHEMISTRY
Information
Patent Grant
Plasmid system
Patent number
11,965,173
Issue date
Apr 23, 2024
AUTOLUS LIMITED
Martin Pulé
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Method for improving retroviral transduction and gene editing in he...
Patent number
11,964,027
Issue date
Apr 23, 2024
Anna Christina Kajaste-Rudnitski
C07 - ORGANIC CHEMISTRY
Information
Patent Grant
Vector production
Patent number
11,957,747
Issue date
Apr 16, 2024
Ospedale San Raffaele S.r.l.
Alessio Cantore
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Grant
Method for NK cell transduction
Patent number
11,957,715
Issue date
Apr 16, 2024
MILTENYI BIOTEC B.V. & CO. KG
Rafijul Bari
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Grant
Compositions and methods for treating diseases and disorders of the...
Patent number
11,957,713
Issue date
Apr 16, 2024
Children's Medical Center Corporation
Alessandra Biffi
A01 - AGRICULTURE FORESTRY ANIMAL HUSBANDRY HUNTING TRAPPING FISHING
Information
Patent Grant
RNA-based delivery systems with levels of control
Patent number
11,946,066
Issue date
Apr 2, 2024
California Institute of Technology
Xiaojing Gao
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Self-assembling insect ferritin nanoparticles
Patent number
11,939,356
Issue date
Mar 26, 2024
The United States of America, as represented by the Secretary, Department of...
Peter Kwong
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Rewiring aberrant cancer signaling to a therapeutic effector respon...
Patent number
11,939,609
Issue date
Mar 26, 2024
The Board of Trustees of the Leland Stanford Junior University
Hokyung Chung
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Genetically modified MSC and therapeutic methods
Patent number
11,939,591
Issue date
Mar 26, 2024
The Regents of the University of California
Jan Nolta
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Methods of treating rheumatoid arthritis using RNA-guided genome ed...
Patent number
11,932,867
Issue date
Mar 19, 2024
National Jewish Health
Brian Freed
A01 - AGRICULTURE FORESTRY ANIMAL HUSBANDRY HUNTING TRAPPING FISHING
Information
Patent Grant
Platform for T lymphocyte genome engineering and in vivo high-throu...
Patent number
11,926,839
Issue date
Mar 12, 2024
Yale University
Sidi Chen
G01 - MEASURING TESTING
Information
Patent Grant
Method of treating HIV-1 infection utilizing a multiepitope T cell...
Patent number
11,919,926
Issue date
Mar 5, 2024
ESTEVE PHARMACEUTICALS, S.A.
Christian Brander
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Genomic RNA packaging enhancer element
Patent number
11,920,147
Issue date
Mar 5, 2024
Case Western Reserve University
Eric J. Arts
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
HIV vaccination compositions comprising vaccinia VLPS and plant-pro...
Patent number
11,918,642
Issue date
Mar 5, 2024
Arizona Board of Regents on behalf of Arizona State University
Tsafrir S. Leket-Mor
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
Methods for expanding hematopoietic stem cells using revitalized me...
Patent number
11,920,159
Issue date
Mar 5, 2024
Albert Einstein College of Medicine
Paul S. Frenette
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Grant
HIV pre-immunization and immunotherapy
Patent number
11,911,458
Issue date
Feb 27, 2024
American Gene Technologies International Inc.
Charles David Pauza
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Grant
Chloride salt of TAT-NR2B9C
Patent number
11,911,438
Issue date
Feb 27, 2024
NoNO Inc.
Jonathan David Garman
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Grant
Methods for screening genetic perturbations
Patent number
11,912,986
Issue date
Feb 27, 2024
The Regents of the University of California
Prashant Mali
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Patents Applications
last 30 patents
Information
Patent Application
Method for Producing Human Chimeric Antigen Receptor T-Cell Populat...
Publication number
20240150713
Publication date
May 9, 2024
PELL BIO-MED TECHNOLOGY CO., LTD.
Chien-Ting LIN
C07 - ORGANIC CHEMISTRY
Information
Patent Application
METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS
Publication number
20240150752
Publication date
May 9, 2024
The Board of Regents of the University of Texas System
Ralf KITTLER
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
EXPEDITED ADMINISTRATION OF ENGINEERED LYMPHOCYTES
Publication number
20240148790
Publication date
May 9, 2024
Kite Pharma, Inc.
Zhenhuan Hu
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING T CELL DYSFUNCTION
Publication number
20240148791
Publication date
May 9, 2024
The Trustees of the University of Pennsylvania
Carl H. June
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
Improved T cell receptor-costimulatory molecule chimera
Publication number
20240148869
Publication date
May 9, 2024
CHINA IMMUNOTECH (BEIJING) BIOTECHNOLOGY CO., LTD
Jiasheng WANG
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
METHODS TO IDENTIFY IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
Publication number
20240150445
Publication date
May 9, 2024
DUKE UNIVERSITY
Barton F. HAYNES
C07 - ORGANIC CHEMISTRY
Information
Patent Application
GENE CODING FOR CHIMERIC RECEPTOR FOR ANTI-ACETYLCHOLINE RECEPTOR A...
Publication number
20240150472
Publication date
May 9, 2024
DAIICHI SANKYO COMPANY, LIMITED
Kazunori Yoshikiyo
C07 - ORGANIC CHEMISTRY
Information
Patent Application
SOLUBLE ALKALINE PHOSPHATASE CONSTRUCTS AND EXPRESSION VECTORS INCL...
Publication number
20240150737
Publication date
May 9, 2024
RAMPART BIOSCIENCE, INC.
JEFFREY S. BARTLETT
C07 - ORGANIC CHEMISTRY
Information
Patent Application
DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM
Publication number
20240148903
Publication date
May 9, 2024
Nanjing GenScript Biotech Co., Ltd.
Weiming WANG
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
LYMPHOCYTE TARGETED LENTIVIRAL VECTORS
Publication number
20240150788
Publication date
May 9, 2024
Kelonia Therapeutics
Molly R. Perkins
C07 - ORGANIC CHEMISTRY
Information
Patent Application
PERSONALIZED REDIRECTION AND REPROGRAMMING OF T CELLS FOR PRECISE T...
Publication number
20240150711
Publication date
May 9, 2024
Dana-Farber Cancer Institute, Inc.
Marc Schwartz
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
UNIVERSAL CAR-T CELL TARGETING GD2, PREPARATION METHOD THEREFOR, AN...
Publication number
20240139321
Publication date
May 2, 2024
NINGBO T-MAXIMUM BIOPHARMACEUTICALS CO., LTD.
Xiaoyun SHANG
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
ENGINEERING HEMAGGLUTININ AND FUSION POLYPEPTIDES OF CANINE DISTEMP...
Publication number
20240141376
Publication date
May 2, 2024
Mayo Foundation for Medical Education and Research
Stephen J. Russell
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
Publication number
20240139294
Publication date
May 2, 2024
Temple University - Of The Commonwealth System of Higher Education
Kamel Khalili
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
COMPOSITIONS AND METHODS TO REDUCE THERAPEUTIC T CELL TOXICITY
Publication number
20240139322
Publication date
May 2, 2024
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC
Marco L. Davila
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
LENTIVIRUS PROTECTION VIA Fc OVEREXPRESSION
Publication number
20240139341
Publication date
May 2, 2024
The Regents of the University of California
Tobias Deuse
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
LENTIVIRUS FOR GENERATING CELLS EXPRESSING ANTI-CD19 CHIMERIC ANTIG...
Publication number
20240141375
Publication date
May 2, 2024
Umoja Biopharma, Inc.
Andrew SCHARENBERG
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
USE OF MESENCHYMAL STEM CELLS OVEREXPRESSING PACER FOR THE TREATMEN...
Publication number
20240141297
Publication date
May 2, 2024
Universidad Mayor
Flavio Carrión Arriagada
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
CAR-T CONSTRUCTS COMPRISING A NOVEL CD19 BINDER COMBINED WITH IL18...
Publication number
20240131068
Publication date
Apr 25, 2024
Kite Pharma, Inc.
Neil C. Sheppard
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
MIR200C-EPCAM AXIS REPROGRAMED IMMUNE CELLS FOR ENHANCED ANTI-TUMOR...
Publication number
20240131073
Publication date
Apr 25, 2024
Memorial Sloan-Kettering Cancer Center
Morgan HUSE
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
IMMUNOGENIC COMPOSITIONS
Publication number
20240131148
Publication date
Apr 25, 2024
The Scripps Research Institute
William R. SCHIEF
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
LARGE SCALE CAR-T IMMUNE CELL MANUFACTURING METHOD UTILIZING LENTIV...
Publication number
20240132841
Publication date
Apr 25, 2024
Kite Pharma, Inc.
Felipe Bedoya
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN R...
Publication number
20240132587
Publication date
Apr 25, 2024
Medimmune, LLC
ALLISON MARIE BARRETT
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
METHODS AND PRODUCTS FOR GENETIC ENGINEERING
Publication number
20240132547
Publication date
Apr 25, 2024
Institut National de la Sante et de la Recherche Medicale (INSERM)
Théophile OHLMANN
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
METHOD OF TREATMENT OF MALARIA BY TARGETTING OPEN READING FRAMES
Publication number
20240132554
Publication date
Apr 25, 2024
CAMBRIDGE ENTERPRISE LIMITED
Sudhakaran PRABAKARAN
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
METHOD FOR REPROGRAMMING HUMAN CELLS
Publication number
20240131080
Publication date
Apr 25, 2024
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Yossi BUGANIM
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
INDUCIBLE SINGLE AAV SYSTEM AND USES THEREOF
Publication number
20240123086
Publication date
Apr 18, 2024
University of Massachusetts
Christian Mueller
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Application
IMMUNE CELLS EXPRESSING AN ANTIGEN BINDING RECEPTOR AND A CHIMERIC...
Publication number
20240122976
Publication date
Apr 18, 2024
Miltneyi Biotec B.V. & Co., KG
Dominik Lock
A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information
Patent Application
D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
Publication number
20240124605
Publication date
Apr 18, 2024
ARCELLX, INC.
David LAFLEUR
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information
Patent Application
DIAGNOSTIC KIT FOR METASTASIS AND INVASION OF BREAST CANCER AND USE...
Publication number
20240124880
Publication date
Apr 18, 2024
ZHEJIANG CHINESE MEDICAL UNIVERSITY
Fangfang TAO
C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...